Investment Thesis
Indaptus Therapeutics is a pre-revenue biotech company with severe cash burn and deteriorating financial health. The company is consuming ~$14.8M in operating cash annually while generating no revenue, with only 8.5M in cash reserves providing roughly 6-7 months of runway at current burn rates. Without demonstrated clinical progress or revenue generation, the company faces imminent liquidity challenges and shareholder dilution.
Strengths
- Positive current ratio of 1.51x indicates short-term liquidity capacity above minimum thresholds
- Minimal long-term debt obligations reduces leverage risk
- Substantial cash position of 8.5M provides near-term operational runway
Risks
- Zero revenue with -19.8M operating loss indicates non-viable business model at present stage
- Annual operating cash burn of -14.8M will exhaust 8.5M cash reserves within 6-7 months without funding
- Negative ROE of -661.5% and ROA of -223.9% demonstrate severe capital inefficiency
- Net loss deteriorated 38.8% YoY indicating worsening financial trajectory
- No disclosed long-term debt suggests future capital raises will require significant equity dilution
- 9 Form 4 insider filings in 90 days may signal uncertainty or opportunistic trading during distress
Key Metrics to Watch
- Monthly cash burn rate and cash runway remaining
- Clinical trial progress and FDA milestone achievements
- Pipeline advancement and partnership announcements
- Capital raise activities and dilution impact on shareholder equity
- Operating expense reduction initiatives
Financial Metrics
Revenue
N/A
Net Income
-20.8M
EPS (Diluted)
$-21.58
Free Cash Flow
-14.8M
Total Assets
9.3M
Cash
8.5M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-661.5%
ROA
-223.9%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
1.51x
Quick Ratio
1.51x
Debt/Equity
0.00x
Debt/Assets
36.5%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-03-29T09:58:10.997258 |
Data as of: 2025-12-31 |
Powered by Claude AI